BACKGROUND: Retrospective studies have shown adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) have superior survival when treated in pediatric versus adult centers (locus of care; LOC). Several adult centers recently adopted pediatric protocols. Whether this has narrowed LOC disparities in real-world settings is unknown. METHODS: The IMPACT Cohort is an Ontario population-based cohort that captured demographic, disease and treatment (treatment protocol, chemotherapy doses) data for all 15-21 year olds diagnosed with ALL 1992-2011. Cancer outcomes were determined by chart abstraction and linkage to provincial healthcare databases. Treatment protocols were classified as pediatric- or adult-based. We examined predicto...
BackgroundStudies show superior outcomes for adolescent and young adult (AYA) patients with acute ly...
BACKGROUND: While several studies have examined the treatment of adolescents and young adults (AYAs)...
It is a new and exciting time for acute lymphoblastic leukemia (ALL). While nearly 50 years ago, onl...
Background Retrospective studies have shown adolescents and young adults (AYA) with acute lymphoblas...
Abstract Background Retrospective studies have shown adolescents and young adults (AYA) with acute l...
Background: The objective was to compare 5-year overall survival (OS) between adolescent and young a...
BackgroundStudies have demonstrated superior outcomes for adolescent and young adult (AYA) patients ...
Hodgkin lymphoma (HL) is a common adolescent and young adult (AYA) cancer. While outcome disparities...
Survival rates of adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) are in...
Adolescents and young adults (AYAs, 15-39 years) with acute lymphoblastic leukemia (ALL) represent a...
Background: Treating adolescents and young adults (AYA) patients with acute lymphoblastic leukemia (...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Background: It remains unclear whether pediatric protocols provide a better outcome to adolescent an...
AbstractBackgroundIt remains unclear whether pediatric protocols provide a better outcome to adolesc...
PurposeWe previously demonstrated lower early mortality for young adults (YAs) with acute lymphoblas...
BackgroundStudies show superior outcomes for adolescent and young adult (AYA) patients with acute ly...
BACKGROUND: While several studies have examined the treatment of adolescents and young adults (AYAs)...
It is a new and exciting time for acute lymphoblastic leukemia (ALL). While nearly 50 years ago, onl...
Background Retrospective studies have shown adolescents and young adults (AYA) with acute lymphoblas...
Abstract Background Retrospective studies have shown adolescents and young adults (AYA) with acute l...
Background: The objective was to compare 5-year overall survival (OS) between adolescent and young a...
BackgroundStudies have demonstrated superior outcomes for adolescent and young adult (AYA) patients ...
Hodgkin lymphoma (HL) is a common adolescent and young adult (AYA) cancer. While outcome disparities...
Survival rates of adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) are in...
Adolescents and young adults (AYAs, 15-39 years) with acute lymphoblastic leukemia (ALL) represent a...
Background: Treating adolescents and young adults (AYA) patients with acute lymphoblastic leukemia (...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Background: It remains unclear whether pediatric protocols provide a better outcome to adolescent an...
AbstractBackgroundIt remains unclear whether pediatric protocols provide a better outcome to adolesc...
PurposeWe previously demonstrated lower early mortality for young adults (YAs) with acute lymphoblas...
BackgroundStudies show superior outcomes for adolescent and young adult (AYA) patients with acute ly...
BACKGROUND: While several studies have examined the treatment of adolescents and young adults (AYAs)...
It is a new and exciting time for acute lymphoblastic leukemia (ALL). While nearly 50 years ago, onl...